Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Nucl Med Commun. 2016 Feb;37(2):122–128. doi: 10.1097/MNM.0000000000000406

Table 2.

FDG PET/CT Findings

Overall (N=24) Surviving
Participants
(N=16)		 Deceased
Participants
(N=8)
Time from Baseline to Follow-up FDG PET/CT 26.08 ± 24.81 27.5 ± 28.87 23.25 ± 14.95
Tumor with the highest baseline SUVmax
  Baseline SUVmax 18.48 ± 10.91 16.62 ± 10.66 22.19 ± 11.14
  Follow-up SUVmax 5.55 ± 3.62 4.92 ± 3.23 6.79 ± 4.26
  Change from Baseline −12.93 ± 9.38 −11.7 ± 9.72 −15.4 ± 8.74
  Percent Change from Baseline −0.68 ± 0.18 −0.68 ± 0.18 −0.67 ± 0.19
Tumor that showed the smallest change in SUVmax between baseline and follow-up
  Baseline SUVmax 10.91 ± 6.72 11.09 ± 6.84 10.59 ± 6.97
  Follow-up SUVmax 6.81 ± 6.29 7.09 ± 6.51 6.34 ± 6.29
  Change from Baseline −4.1 ± 4.81 −4.01 ± 4.93 −4.25 ± 4.92
  Percent Change from Baseline −0.40 ± 0.34 −0.39 ± 0.38 −0.42 ± 0.27

Number of Patients with Overall change in SUVmax of 0–50%: 5

Number of Patients with Overall change in SUVmax of 50–100%: 19